The United Kingdom and the United States have established a major trade agreement that will keep zero levies on UK drug shipments being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost funding on medicines through the National Health Service (NHS). This move guarantees that duties on these vital goods will remain at zero for a timeframe of the next three years.
This deal follows previous statements to hike import taxes on branded pharmaceutical imports, with potential rates mentioned up to double the cost.
"This deal between the UK reinforces the worldwide climate for cutting-edge drugs and establishes much-needed equity to American-British pharmaceutical trade," a statement said.
Economic Impact
Drugs represent one of the Britain's most significant export categories to the US, which is easily the largest market for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This value accounted for a significant portion of total UK exports in that span.
"This guarantee secures work, increases investment and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The deal includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to raise overall NHS spending on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
The deal takes place against a ongoing row between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that US consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while major investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
